Ospemifene
- Generic Name
- Ospemifene
- Brand Names
- Osphena, Senshio
- Drug Type
- Small Molecule
- Chemical Formula
- C24H23ClO2
- CAS Number
- 128607-22-7
- Unique Ingredient Identifier
- B0P231ILBK
- Background
Ospemifene is a new selective non-hormonal estrogen receptor modulator (SERM) that is used for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause. FDA approved on February 26, 2013.
- Indication
Ospemifene is indicated for the treatment of moderate to severe dyspareunia and vaginal dryness associated with menopause.
- Associated Conditions
- Moderate Dyspareunia, Moderate Vaginal dryness, Severe Dyspareunia, Severe Vaginal dryness
- Associated Therapies
- -
Ospemifene vs. Conjugated Estrogens in the Treatment of Postmenopausal Sexual Dysfunction
Phase 4
Terminated
- Conditions
- Interventions
- First Posted Date
- 2017-01-11
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Emory University
- Target Recruit Count
- 1
- Registration Number
- NCT03018106
- Locations
- 🇺🇸
Emory Hospital, Atlanta, Georgia, United States
🇺🇸Emory Midtown Hospital, Atlanta, Georgia, United States
🇺🇸Emory Clinic, Atlanta, Georgia, United States
Vulvoscopy Changes of the Vulva, Vestibule and Vagina With Daily Ospemifene in Women With Dyspareunia From VVA
- First Posted Date
- 2016-05-27
- Last Posted Date
- 2019-04-02
- Lead Sponsor
- Sue Goldstein
- Target Recruit Count
- 10
- Registration Number
- NCT02784613
- Locations
- 🇺🇸
San Diego Sexual Medicine, San Diego, California, United States
Study to Evaluate Ospemifene in Patients With Moderate to Severe Vaginal Dryness Due to Menopause
- First Posted Date
- 2015-12-23
- Last Posted Date
- 2019-04-02
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 631
- Registration Number
- NCT02638337
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath